Maze Therapeutics, Inc. (MAZE) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 21 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Tue, Aug 11, 2026after close 42 8-K
Q1 FY2026Tue, May 12, 2026after close 42 8-K
Q4 FY2025Wed, Mar 25, 2026before open 84 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Tue, Aug 12, 2025after close 43 8-K
Q1 FY2025Wed, May 14, 2025after close 44 8-K
Q4 FY2024Mon, Mar 31, 2025before open 90 8-K

What they guided beta

Q3 FY2026 "Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment ongoing in Phase 2 CIPheR trial of MZE782 in PKU; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $477 million in cash, cash equivalents and marketable securities as of September 30, 2026 supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision med" exhibit
Q3 FY2026 "In early 2027, Maze expects to announce the final data from HORIZON which is designed to evaluate the potential of MZE829 to treat each of three AMKD patient subgroups: AMKD without diabetes, AMKD with diabetes and AMKD with focal segmental glomerulosclerosis (FSGS)." exhibit
Q3 FY2026 "Topline data from the trial is expected in 2027." exhibit
Q3 FY2026 "Maze expects that its current cash, cash equivalents and marketable securities will fund operations into 2029 based on its current business plan." exhibit
Q2 FY2026 "Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., August 11, 2026 (GLOBE NEWSWIRE) – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicine" exhibit
Q2 FY2026 "“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in 2027, and continued strong enrollment in the Phase 2 HORIZON trial of MZE829 across three cohorts with additional data on track for 10-15 patients per cohort in late 2026 or early 2027,” said Jason Coloma, Ph.D., chief executive officer of Maze." exhibit
Q2 FY2026 "With a strong balance sheet and expected cash runway into 2029, we are well positioned to execute against the clinical milestones in our pipeline.”" exhibit
Q2 FY2026 "Maze continues to enroll the HORIZON trial, and expects to announce updated data in late 2026 or early 2027 on three 10-15 patient cohorts: AMKD without diabetes, AMKD with diabetes and AMKD with severe focal segmental glomerulosclerosis (FSGS)." exhibit
Q2 FY2026 "Topline data from the trial is expected in 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MAZE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MAZE

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

MAZE earnings date badge

HTML

<a href="https://veritasdata.dev/company/MAZE/"><img src="https://veritasdata.dev/embed/MAZE.svg" alt="MAZE earnings date" width="240" height="56"></a>

Markdown

[![MAZE earnings date](https://veritasdata.dev/embed/MAZE.svg)](https://veritasdata.dev/company/MAZE/)

Script

<script async src="https://veritasdata.dev/embed/MAZE.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MAZE"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.